Blood Test and Voice Analysis to Help Diagnose Dementia in People with Cognitive Complaints

What this Trial Is About

Researchers are evaluating whether a blood test measuring a brain protein called Neurofilament light chain NfL can help diagnose dementia in people who have cognitive complaints. This observational cohort study includes participants presenting to a single healthcare network and also assesses changes in language through speech tests. The study addresses challenges in current dementia diagnosis, including limitations in standard cognitive tests and access to advanced brain imaging, especially in diverse populations. Participants will have a single blood draw and speech test when they first present to the clinic or hospital. They will be followed up after 12 months, during which they will complete questionnaires and cognitive assessments over the phone, and repeat the speech test. Individuals at risk for Fronto-temporal dementia may also opt for genetic testing using a saliva sample collected at home. Throughout the study, researchers will measure baseline NfL levels and monitor changes in speech and language processing over time. The study aims to develop accessible and cost-effective diagnostic tools to improve dementia diagnosis pathways. Participation involves initial testing and a follow-up at 12 months, with ongoing assessments conducted remotely. The study is sponsored by Monash University and is expected to continue until December 2027.

Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis